Silo Pharma Inc. Nears Critical Milestone in PTSD Treatment Development

Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company, is approaching a significant milestone in its development of SPC-15, a novel intranasal prophylactic aimed at enhancing stress resilience and preventing Post-Traumatic Stress Disorder (PTSD). The company anticipates receiving data from two crucial preclinical studies within the next 30 to 90 days. These studies include IND-enabling GLP-compliant toxicology and toxicokinetic testing, as well as a large animal safety study requested by the FDA. The outcomes of these studies are essential for the company's planned Investigational New Drug (IND) application, with submission targeted before the year's end.

The development of SPC-15 is of particular importance due to the scarcity of new treatments for PTSD, a condition that impacts millions globally. The last FDA-approved drug for PTSD was introduced nearly 25 years ago, highlighting the urgent need for innovative therapies. Silo Pharma's approach, which involves novel formulations and drug-delivery systems, could provide a much-needed alternative to existing treatments. Success in the upcoming studies could enable a Phase 1 clinical trial by 2026, utilizing the FDA's 505(b)(2) pathway to accelerate the development process.

For further details on Silo Pharma's groundbreaking research and development initiatives, visit https://www.SiloPharma.com. The potential of SPC-15 to transform PTSD treatment underscores the significance of the forthcoming study results, not only for Silo Pharma but also for the broader medical community and patients awaiting new therapeutic options.